Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review

Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2− tumors, adjuvant endocrine therapy (ET) is the cornerstone treatment. Although relapse events steadily continue, the ET benefits translate to dramatically...

Full description

Bibliographic Details
Main Authors: Danilo Giffoni de Mello Morais Mata, Carlos Amir Carmona, Andrea Eisen, Maureen Trudeau
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Oncology
Subjects:
early breast cancer
premenopausal
postmenopausal
hormone receptor positive
HER2-negative
endocrine therapy
Online Access:https://www.mdpi.com/1718-7729/29/7/394

Internet

https://www.mdpi.com/1718-7729/29/7/394

Similar Items